Literature DB >> 19780403

Magnesium in major depression.

Mihai Nechifor1.   

Abstract

There are contradictory data regarding the levels of magnesium in patients with major depression (MD) and how antidepressants influence their concentration. Our results show erythrocyte magnesium in patients with MD (44.39 +/- 2.7 mg/L vs. 59.1 +/- 3.2 mg/L in control group, p < 0.05) and only in patients with severe MD (Hamilton score > 23) was a moderate decrease in plasmatic magnesium observed (17.7 +/- 1.5 mg/L vs. 22.9 +/- 3.3 mg/L in control group). Therapy with antidepressants from different groups and with different mechanisms of action, such as amytriptiline (25 mg x 3/day per os, 4 weeks) and sertraline (50 mg x 3/day per os, 4 weeks) leads to a significant increase of magnesium concentration in erythrocytes (57.6 +/- 4.5 mg/L after amytriptiline, respectively 56.9 +/- 3.2 mg/L after sertraline, p < 0.05 vs. before therapy). At the same time, in patients with MD, plasmatic levels of zinc were significantly decreased before therapy and increased after treatment with amytriptiline and sertraline (0.68 +/- 0.09 mg/L before treatment vs. 0.9 +/- 0.07 after amytriptiline). There is a positive correlation between concentrations of magnesium in erythrocytes and the clinical evolution of patients with MD. We consider that increasing intracellular concentration is a component of the antidepressant mechanism of sertraline and amytriptiline and maybe of other antidepressants. Anhedonia and autolytic tendencies are important elements of MD symptomatology. We tested the influence of MgCl2 0.2 mM/kg/day on a reward system using conditioned place preference (Panlab) in rats. Our data show a moderate stimulation of the reward system by magnesium (290.6 +/- 27 s time spent in a conditioned compartment before magnesium treatment and 363.3 +/- 16 s after magnesium treatment) that reflects a stimulation of the reward system (RS). We consider that a magnesium-induced stimulation of the RS is an important issue for treating anhedonia in patients with MD. An increase of intracellular magnesium may be part of the mechanism of action of antidepressants.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19780403

Source DB:  PubMed          Journal:  Magnes Res        ISSN: 0953-1424            Impact factor:   1.115


  12 in total

1.  A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients.

Authors:  Haeseong Park; Gwendolyn L Parker; Cecelia H Boardman; Monica M Morris; Thomas J Smith
Journal:  Support Care Cancer       Date:  2011-01-27       Impact factor: 3.603

2.  North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes.

Authors:  Haeseong Park; Rui Qin; Thomas J Smith; Pamela J Atherton; Debra L Barton; Keren Sturtz; Shaker R Dakhil; Daniel M Anderson; Kathleen Flynn; Suneetha Puttabasavaiah; Nguyet Anh Le-Lindqwister; Gilbert D A Padula; Charles L Loprinzi
Journal:  Menopause       Date:  2015-06       Impact factor: 2.953

Review 3.  Magnesium Orotate and the Microbiome-Gut-Brain Axis Modulation: New Approaches in Psychological Comorbidities of Gastrointestinal Functional Disorders.

Authors:  Cristina Schiopu; Gabriela Ștefănescu; Smaranda Diaconescu; Gheoghe G Bălan; Nicoleta Gimiga; Elena Rusu; Cosmin Alec Moldovan; Bogdan Popa; Elena Tataranu; Andrei Vasile Olteanu; Alexandra Boloș; Cristinel Ștefănescu
Journal:  Nutrients       Date:  2022-04-09       Impact factor: 6.706

4.  Role of magnesium supplementation in the treatment of depression: A randomized clinical trial.

Authors:  Emily K Tarleton; Benjamin Littenberg; Charles D MacLean; Amanda G Kennedy; Christopher Daley
Journal:  PLoS One       Date:  2017-06-27       Impact factor: 3.240

Review 5.  The Importance of Magnesium in Clinical Healthcare.

Authors:  Gerry K Schwalfenberg; Stephen J Genuis
Journal:  Scientifica (Cairo)       Date:  2017-09-28

Review 6.  The Role of Magnesium in Neurological Disorders.

Authors:  Anna E Kirkland; Gabrielle L Sarlo; Kathleen F Holton
Journal:  Nutrients       Date:  2018-06-06       Impact factor: 5.717

7.  Intra-erythrocytes magnesium deficiency could reflect cognitive impairment status due to vascular disease: a pilot study.

Authors:  Clementina Sitzia; Michele Sterlicchio; Calogero Crapanzano; Elena Dozio; Elena Vianello; Massimiliano Marco Corsi Romanelli
Journal:  J Transl Med       Date:  2020-12-03       Impact factor: 5.531

Review 8.  Magnesium in Aging, Health and Diseases.

Authors:  Mario Barbagallo; Nicola Veronese; Ligia J Dominguez
Journal:  Nutrients       Date:  2021-01-30       Impact factor: 5.717

9.  MAGnesium-oral supplementation to reduce PAin in patients with severe PERipheral arterial occlusive disease: the MAG-PAPER randomised clinical trial protocol.

Authors:  Monica Aida Venturini; Sergio Zappa; Cosetta Minelli; Stefano Bonardelli; Laura Lamberti; Luca Bisighini; Marta Zangrandi; Maddalena Turin; Francesco Rizzo; Andrea Rizzolo; Nicola Latronico
Journal:  BMJ Open       Date:  2015-12-16       Impact factor: 2.692

10.  Effects of Magnesium Supplementation on Unipolar Depression: A Placebo-Controlled Study and Review of the Importance of Dosing and Magnesium Status in the Therapeutic Response.

Authors:  Beata Ryszewska-Pokraśniewicz; Anna Mach; Michał Skalski; Piotr Januszko; Zbigniew M Wawrzyniak; Ewa Poleszak; Gabriel Nowak; Andrzej Pilc; Maria Radziwoń-Zaleska
Journal:  Nutrients       Date:  2018-08-03       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.